Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Amoy Diagnostics Co., Ltd. (300685.SZ)
CNY18.57
+0.66 (+3.69%)
CN SHZ Healthcare Medical - Diagnostics & Research
Address
39 Dingshan Road 361027
Xiamen, CN
Xiamen, CN
CEO
Jiemin Luo
Website
amoydx.com
IPO
2017-08-03
ISIN CNE1000034D3
Description
Amoy Diagnostics Co., Ltd. is a diagnostics company focused on molecular diagnostic solutions for precision oncology. Operating both within China and across international markets, the firm provides a range of sophisticated assays, including Next-Generation Sequencing (NGS), real-time PCR, Fluorescence In Situ Hybridization (FISH), and various extraction methods. Established in 2008, Amoy Diagnostics has its base in Xiamen, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY18.57
+0.66 (+3.69%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
10M
Beta
0.36
Float Shares
279.17M
Free Float %
71.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.34% | +7.48% | +0.99% | -2.44% | -7.27% | -0.24% | -2.20% | -22.72% | -59.36% | +396.59% | +396.59% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
18.57
DCF (Unlevered)
28.98
+56.1%
DCF (Levered)
25.75
+38.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
16.76
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
8 / 10
Strong MOAT
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
4 / 5
High
P/E Score
2 / 5
Medium
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
★ Strong MOAT
-
Revenue growth Medical - Diagnostics & Research: +7.9%+8.0% ★ Q1'26: -4.3% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+42.2% ★ Q1'26: -4.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+19.0% Q1'26: +36.3% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+30.2% ★ Q1'26: +38.6% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+38.0% ★ Q1'26: +55.4% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%-0.1% ★ Q1'26: -0.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.30× ★ Q1'26: 0.05× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 5 Rev. Ana. 4 EPS Ana. |
Dec 2028 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
330.37M
est: 345.00M (-4.2%)
|
439.03M
est: 438.73M (+0.1%)
|
578.36M
est: 588.00M (-1.6%)
|
728.39M
est: 728.26M (+0.0%)
|
939.72M
est.
|
917.03M
est: 841.55M (+9.0%)
|
1.04B
est: 1.13B (-7.5%)
|
842.18M
est: 1.13B (-25.3%)
|
1.11B
est: 1.26B (-12.0%)
|
1.20B
est: 1.23B (-3.0%)
|
1.36B
1.33B – 1.42B
+10.4% YoY
|
1.56B
1.49B – 1.69B
+14.3% YoY
|
1.79B
1.73B – 1.85B
+15.1% YoY
|
| EBITDA |
123.75M
est: 96.79M (+27.9%)
|
162.83M
est: 123.09M (+32.3%)
|
185.85M
est: 164.96M (+12.7%)
|
229.32M
est: 204.31M (+12.2%)
|
263.64M
est.
|
289.23M
est: 236.10M (+22.5%)
|
349.20M
est: 384.28M (-9.1%)
|
335.30M
est: 384.28M (-12.7%)
|
337.57M
est: 429.35M (-21.4%)
|
420.47M
est: 420.74M (-0.1%)
|
464.48M
452.84M – 485.30M
+10.4% YoY
|
531.07M
506.29M – 575.36M
+14.3% YoY
|
611.21M
590.41M – 632.01M
+15.1% YoY
|
| EBIT |
107.36M
est: 81.19M (+32.2%)
|
143.12M
est: 103.25M (+38.6%)
|
161.60M
est: 138.38M (+16.8%)
|
201.99M
est: 171.38M (+17.9%)
|
221.15M
est.
|
252.78M
est: 198.04M (+27.6%)
|
296.43M
est: 330.71M (-10.4%)
|
287.48M
est: 330.71M (-13.1%)
|
291.57M
est: 369.49M (-21.1%)
|
361.88M
est: 362.09M (-0.1%)
|
399.73M
389.71M – 417.65M
+10.4% YoY
|
457.03M
435.71M – 495.15M
+14.3% YoY
|
526.01M
508.10M – 543.91M
+15.1% YoY
|
| Net Income |
94.07M
est: 109.80M (-14.3%)
|
126.74M
est: 132.74M (-4.5%)
|
135.47M
est: 137.16M (-1.2%)
|
180.33M
est: 191.79M (-6.0%)
|
247.25M
est.
|
239.57M
est: 286.98M (-16.5%)
|
261.48M
est: 278.58M (-6.1%)
|
263.74M
est: 278.58M (-5.3%)
|
254.86M
est: 318.07M (-19.9%)
|
361.26M
est: 374.82M (-3.6%)
|
406.93M
406.49M – 444.67M
+8.6% YoY
|
471.98M
463.93M – 512.34M
+16.0% YoY
|
533.12M
525.42M – 589.59M
+13.0% YoY
|
| SGA |
154.60M
est: 139.69M (+10.7%)
|
196.55M
est: 177.64M (+10.6%)
|
289.53M
est: 238.09M (+21.6%)
|
329.91M
est: 294.88M (+11.9%)
|
380.50M
est.
|
364.31M
est: 340.75M (+6.9%)
|
384.71M
est: 424.97M (-9.5%)
|
360.44M
est: 424.97M (-15.2%)
|
418.83M
est: 474.81M (-11.8%)
|
374.18M
est: 465.30M (-19.6%)
|
513.67M
500.79M – 536.69M
+10.4% YoY
|
587.30M
559.90M – 636.28M
+14.3% YoY
|
675.93M
652.92M – 698.94M
+15.1% YoY
|
| EPS |
0.28
est: 0.28 (+1.6%)
|
0.33
est: 0.33 (-1.0%)
|
0.35
est: 0.34 (+1.6%)
|
0.46
est: 0.48 (-4.5%)
|
0.62
est.
|
0.60
est: 0.72 (-16.7%)
|
0.66
est: 0.70 (-5.7%)
|
0.67
est: 0.70 (-4.3%)
|
0.64
est: 0.79 (-19.0%)
|
0.91
est: 0.93 (-2.2%)
|
1.06
1.02 – 1.12
+13.5% YoY
|
1.23
1.17 – 1.29
+15.9% YoY
|
1.40
1.32 – 1.48
+14.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-28 | A | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-27 | A | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-26 | A | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-25 | A | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-22 | A | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-21 | A | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-20 | A | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-19 | A | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 3/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
311.11M
OE per share TTM
0.79
Owner's Yield
3.91%
Maintenance CapEx ratio
18.22%
Maint CapEx / Avg PPE
20.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 21 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | VanEck - China New Economy ETF CNEW.AX | 0.73% | 514.4K | 0.95% |
| 2 | JPMorgan ETFs (Ireland) ICAV - China A Research Enhanced Index Equity Active UCITS ETF JREC.L | 0.10% | 22.3K | 0.40% |
| 3 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 60.9K | 0.65% |
| 4 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 314.4K | 0.06% |
| 5 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 149.8K | 0.39% |
| 6 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 7.3K | 0.44% |
| 7 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 101.6K | 0.29% |
| 8 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 93.6K | 0.28% |
| 9 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 21.6K | 0.26% |
| 10 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 9.6K | 0.48% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
316.3K
Shares Outstanding
390.11M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Frank Ron Zheng | Deputy GM & Director | — | male |
| Hongyu Wang | Deputy General Manager | — | male |
| Huibin Zheng | Deputy General Manager | — | male |
| Jiemin Luo | GM & Director | — | male |
| Ruan Li | Deputy GM, Chief Technology Officer & Director | — | male |
| Ying Chen | Chief Financial Officer, Accounting Supervisor & Secretary to the Board of Directors | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300685.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
